Switch theme
Sign up to access all valuation multiples
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. The company also conducts consulting and technical services. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.
1997
765
LTM Revenue $116M
Last FY EBITDA $30.3M
$367M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Scinopharm Taiwan has a last 12-month revenue (LTM) of $116M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Scinopharm Taiwan achieved revenue of $114M and an EBITDA of $30.3M.
Scinopharm Taiwan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Scinopharm Taiwan valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $116M | XXX | $114M | XXX | XXX | XXX |
| Gross Profit | $44.2M | XXX | $43.4M | XXX | XXX | XXX |
| Gross Margin | 38% | XXX | 38% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $30.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 27% | XXX | XXX | XXX |
| EBIT | $11.3M | XXX | $10.8M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $10.8M | XXX | $11.3M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Scinopharm Taiwan's stock price is TWD 17 (or $1).
Scinopharm Taiwan has current market cap of TWD 13.4B (or $447M), and EV of TWD 11.0B (or $367M).
See Scinopharm Taiwan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $367M | $447M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Scinopharm Taiwan has market cap of $447M and EV of $367M.
Scinopharm Taiwan's trades at 3.2x EV/Revenue multiple, and 12.1x EV/EBITDA.
Equity research analysts estimate Scinopharm Taiwan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Scinopharm Taiwan has a P/E ratio of 41.5x.
See valuation multiples for Scinopharm Taiwan and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $447M | XXX | $447M | XXX | XXX | XXX |
| EV (current) | $367M | XXX | $367M | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 12.1x | XXX | XXX | XXX |
| EV/EBIT | 32.4x | XXX | 34.1x | XXX | XXX | XXX |
| EV/Gross Profit | 8.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 41.5x | XXX | 39.5x | XXX | XXX | XXX |
| EV/FCF | 21.0x | XXX | 23.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialScinopharm Taiwan's last 12 month revenue growth is 2%
Scinopharm Taiwan's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $43K for the same period.
Scinopharm Taiwan's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Scinopharm Taiwan's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Scinopharm Taiwan and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 28% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $43K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scinopharm Taiwan acquired XXX companies to date.
Last acquisition by Scinopharm Taiwan was XXXXXXXX, XXXXX XXXXX XXXXXX . Scinopharm Taiwan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Scinopharm Taiwan founded? | Scinopharm Taiwan was founded in 1997. |
| Where is Scinopharm Taiwan headquartered? | Scinopharm Taiwan is headquartered in Taiwan. |
| How many employees does Scinopharm Taiwan have? | As of today, Scinopharm Taiwan has 765 employees. |
| Is Scinopharm Taiwan publicy listed? | Yes, Scinopharm Taiwan is a public company listed on TAI. |
| What is the stock symbol of Scinopharm Taiwan? | Scinopharm Taiwan trades under 1789 ticker. |
| When did Scinopharm Taiwan go public? | Scinopharm Taiwan went public in 2011. |
| Who are competitors of Scinopharm Taiwan? | Similar companies to Scinopharm Taiwan include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Scinopharm Taiwan? | Scinopharm Taiwan's current market cap is $447M |
| What is the current revenue of Scinopharm Taiwan? | Scinopharm Taiwan's last 12 months revenue is $116M. |
| What is the current revenue growth of Scinopharm Taiwan? | Scinopharm Taiwan revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Scinopharm Taiwan? | Current revenue multiple of Scinopharm Taiwan is 3.2x. |
| Is Scinopharm Taiwan profitable? | Yes, Scinopharm Taiwan is EBITDA-positive (as of the last 12 months). |
| What is the current FCF of Scinopharm Taiwan? | Scinopharm Taiwan's last 12 months FCF is $17.5M. |
| What is Scinopharm Taiwan's FCF margin? | Scinopharm Taiwan's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Scinopharm Taiwan? | Current FCF multiple of Scinopharm Taiwan is 21.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
